share_log

PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.

PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.

pavmed股票交易上漲,因爲該公司宣佈與Lucid Diagnostics提交了Esoguard食管DNA檢測的完整臨床證據。
Benzinga ·  11/20 21:38

PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.

pavmed的股票在公司宣佈與Lucid Diagnostics提交其Esoguard食道DNA檢測的完整臨床證據後上漲。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論